Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company

MarketBeat

PDS Biotechnology Q1 Earnings Call Highlights

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank

MarketBeat

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June. Speaking at an investor conference, a Caris executive identified by Chief Scientific

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the fi

MarketBeat

Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year. On the company’s first-quarter 2026 earnings call

MarketBeat

McKesson Q4 Earnings Call Highlights

McKesson (NYSE:MCK) reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 20

MarketBeat

Ann Barrett obituary

Oncologist and authority on paediatric radiotherapy who championed a multidisciplinary, holistic approach

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

MarketBeat

Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.

International Business Times

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MarketBeat

Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains a 100% “Buy” technical opinion from Barchart. Wall Street sentiment is bullish with multiple “Strong Buy” ratings and price targets...

Barchart

Repurposed Antiparasitic Drugs in Cancer Research: What the Science Says About Fenbendazole and Mebendazole

The concept of drug repurposing has gained substantial momentum in oncology research over the past several years. Among the most discussed candidates in this emerging field are benzimidazole antiparasitic agents, particularly fenbendazole.

Medical Daily

Decoding the Warning Signs: 10 Behaviour Changes Demanding Attention

Pets communicate through actions and it holds true for happiness as well as distress. Dr. Abhishek Choudhary, Veterinarian, Vetic, looks at 10 common behaviour changes that can signal illness, discomfort, or ageing-related issues in pets. He will also explain why prompt veterinary care is essential when you notice these signs…

Times Pets

Little Heroes: EU Parliament pays tribute to child cancer victims with Brussels art exhibition

Part of the European Parliament in Brussels has been transformed into a glowing artistic tribute space this week to display colourful paintings from the Children's Oncology Unit of Makareio Hospital in Cyprus

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

MyLifeXP

Free HPV Vaccine for Girls What Parents Need to Know

Human Papillomavirus or HPV is a group of more than 100 related viruses, some of which are classified as high risk types because they can cause cancer. Persistent infection with high risk HPV strains, particularly HPV 16 and HPV 18, is responsible for the majority of cervical cancer cases globally.…

Euronews

'Cuba's healthcare system is being pushed to the brink by US blockades,' says health minister

Cuba’s Health Minister says the country is headed to a catastrophic humanitarian crisis, saying the US blockade of oil on his country is rendering hospitals helpless and puts thousands of lives at risk.

The Times of India

Who is Kashyap Patel? Indian-origin doctor wins prestigious NRI award Hind Rattan for transforming cancer care

Kashyap Patel, an Indian-origin physician, has been honored with the prestigious Hind Rattan Award for his two decades of work in community oncology. He is recognized for championing equitable access to high-quality cancer care, particularly for rural and underserved populations, and advocating for patient-centered treatment beyond major urban hospitals.

Barchart

1 Under-$10 Stock Set to Surge as Much as 850% in 2026

Kura is a classic high-risk, high-reward biotech investment that has entered a vital growth phase.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Exelixis Reports Solid Earnings—Are New Highs Back on the Table?

Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion

MarketBeat

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

Fortune

'We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The winners always stand up again."

MarketBeat

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

International Business Times

Inside CTOAM's Precision Oncology Approach and Its Focus on Advanced Diagnostics With Individual Cancer Patients' Needs

At the core of CTOAM's work, Morand explains, is a precision oncology process that integrates multiple diagnostic tools into a single, coordinated pathway. The company supports tumor DNA and RNA sequencing, whole genome liquid biopsies for real-time monitoring, and advanced imaging, including PET-CT scans, depending on what each individual case…

MarketBeat

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

Barchart

This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Parliament

870 stories

Eli Lilly

749 stories

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.